Advanced Accelerator Applications SA (NASDAQ:AAAP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday. The firm currently has a $44.00 price target on the stock. Zacks Investment Research’s price target suggests a potential upside of 15.76% from the company’s previous close.

According to Zacks, “Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company, develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The company’s commercial products include Gluscan /Gluscan 500/Barnascan(R), IASOflu(R), IASOdopa(R), IASOcholine(R), MIBITEC/Adamibi and Leukokit(R). It operates primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany and Canada. Advanced Accelerator Applications S.A. is headquartered in Saint Genis Pouilly, France. “

Analyst Recommendations for Advanced Accelerator Applications SA (NASDAQ:AAAP)

Advanced Accelerator Applications SA (NASDAQ:AAAP) opened at 38.01 on Tuesday. The company’s market capitalization is $1.49 billion. Advanced Accelerator Applications SA has a 12-month low of $18.00 and a 12-month high of $39.66. The stock’s 50 day moving average price is $36.47 and its 200 day moving average price is $32.93.

Advanced Accelerator Applications SA (NASDAQ:AAAP) last released its quarterly earnings results on Wednesday, August 31st. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.05. Advanced Accelerator Applications SA had a negative net margin of 12.87% and a negative return on equity of 8.50%. On average, equities research analysts anticipate that Advanced Accelerator Applications SA will post ($0.44) earnings per share for the current fiscal year.

Several large investors have recently added to or reduced their stakes in AAAP. Lazard Asset Management LLC bought a new stake in Advanced Accelerator Applications SA during the first quarter valued at $276,000. United Services Automobile Association boosted its stake in Advanced Accelerator Applications SA by 60.4% in the second quarter. United Services Automobile Association now owns 12,673 shares of the company’s stock valued at $383,000 after buying an additional 4,771 shares during the last quarter. Royce & Associates LP bought a new stake in Advanced Accelerator Applications SA during the second quarter valued at $454,000. Alps Advisors Inc. boosted its stake in Advanced Accelerator Applications SA by 27.2% in the second quarter. Alps Advisors Inc. now owns 55,178 shares of the company’s stock valued at $1,668,000 after buying an additional 11,796 shares during the last quarter. Finally, Vivo Capital LLC bought a new stake in Advanced Accelerator Applications SA during the first quarter valued at $15,962,000. Institutional investors and hedge funds own 16.28% of the company’s stock.

Advanced Accelerator Applications SA Company Profile

Advanced Accelerator Applications SA is a radiopharmaceutical company that develops, produces and sells molecular nuclear medicine (MNM), diagnostic and therapeutic products. The Company’s lead therapeutic candidate, Lutathera, is being developed for the treatment of midgut neuroendocrine tumors (NETs).

5 Day Chart for NASDAQ:AAAP

Receive News & Stock Ratings for Advanced Accelerator Applications SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Accelerator Applications SA and related stocks with our FREE daily email newsletter.